Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage ( Seite 69)

wer ist eigentlich hier noch investiert ausser mir?

ich und wahrscheinlich noch tausende.

http://www.spiegel.de/wissenschaft/mensch/0,1518,635490,00.html

Ich bin auch noch drinn und werde es auch bleiben!
Wenn man auf jede gute oder schlechte Nachricht mit hysterie regiert wird das nix
Ich seh hier einfach noch viel potential...insidergeschäfte hin oder her!

Antwort auf Beitrag Nr.: 37.550.412 von 360 am 10.07.09 17:11:58Weiss auch nicht, würde mich schon reizen wieder eine anfangsposition aufzubauen, aber irgendwie hätte ich noch etwas tiefere Kurse erwartet, so um 2,25-2,30 USD. Da würde ich auf jeden Fall zugreifen, aber es sieht ja eher nicht so aus, als wenn es da noch hingeht.

Schauer mer mal....Prinzipell sieht der Chart trotz Insiderverkäufe nicht soooo schlecht aus. Schließlich kommt Nova von unter 1 USD

Antwort auf Beitrag Nr.: 37.550.412 von 360 am 10.07.09 17:11:58langsam wird die Katze aus dem Sack gelassen......


Pandemic (H1N1) 2009 briefing note 2
WHO recommendations on pandemic (H1N1) 2009 vaccines

13 JULY 2009 | GENEVA -- On 7 July 2009, the Strategic Advisory Group of Experts (SAGE) on Immunization held an extraordinary meeting in Geneva to discuss issues and make recommendations related to vaccine for the pandemic (H1N1) 2009.

SAGE reviewed the current pandemic situation, the current status of seasonal vaccine production and potential A(H1N1) vaccine production capacity, and considered potential options for vaccine use.

The experts identified three different objectives that countries could adopt as part of their pandemic vaccination strategy:

* protect the integrity of the health-care system and the country's critical infrastructure;
* reduce morbidity and mortality; and
* reduce transmission of the pandemic virus within communities.

Countries could use a variety of vaccine deployment strategies to reach these objectives but any strategy should reflect the country’s epidemiological situation, resources and ability to access vaccine, to implement vaccination campaigns in the targeted groups, and to use other non-vaccine mitigation measures.

Although the severity of the pandemic is currently considered to be moderate with most patients experiencing uncomplicated, self-limited illness, some groups such as pregnant women and persons with asthma and other chronic conditions such as morbid obesity appear to be at increased risk for severe disease and death from infection.

Since the spread of the pandemic virus is considered unstoppable, vaccine will be needed in all countries. SAGE emphasized the importance of striving to achieve equity among countries to access vaccines developed in response to the pandemic (H1N1) 2009

The following recommendations were provided to the WHO Director-General:

* All countries should immunize their health-care workers as a first priority to protect the essential health infrastructure. As vaccines available initially will not be sufficient, a step-wise approach to vaccinate particular groups may be considered. SAGE suggested the following groups for consideration, noting that countries need to determine their order of priority based on country-specific conditions: pregnant women; those aged above 6 months with one of several chronic medical conditions; healthy young adults of 15 to 49 years of age; healthy children; healthy adults of 50 to 64 years of age; and healthy adults of 65 years of age and above.
* Since new technologies are involved in the production of some pandemic vaccines, which have not yet been extensively evaluated for their safety in certain population groups, it is very important to implement post-marketing surveillance of the highest possible quality. In addition, rapid sharing of the results of immunogenicity and post-marketing safety and effectiveness studies among the international community will be essential for allowing countries to make necessary adjustments to their vaccination policies.
* In view of the anticipated limited vaccine availability at global level and the potential need to protect against "drifted" strains of virus, SAGE recommended that promoting production and use of vaccines such as those that are formulated with oil-in-water adjuvants and live attenuated influenza vaccines was important.
* As most of the production of the seasonal vaccine for the 2009-2010 influenza season in the northern hemisphere is almost complete and is therefore unlikely to affect production of pandemic vaccine, SAGE did not consider that there was a need to recommend a "switch" from seasonal to pandemic vaccine production.

WHO Director-General Dr Margaret Chan endorsed the above recommendations on 11 July 2009, recognizing that they were well adapted to the current pandemic situation. She also noted that the recommendations will need to be changed if and when new evidence become available.

SAGE was established by the WHO Director-General in 1999 as the principal advisory group to WHO for vaccines and immunization. It comprises 15 members who serve in their personal capacity and represent a broad range of disciplines from around the world in the fields such as epidemiology, public health, vaccinology, paediatrics, internal medicine, infectious diseases, immunology, drug regulation, programme management, immunization delivery, and health-care administration.

Additional participants in the SAGE meeting included members of the ad hoc policy advisory working group on influenza A(H1N1) vaccine, chairs of the regional technical advisory groups and external experts. Observers included industry representatives and regulators who did not take part in the recommendation process in order to avoid conflicts of interest.

RELATED LINKS
Strategic Advisory Group of Experts (SAGE) on Immunization

Pandemic (H1N1) 2009: full coverage
------------------------------

gruß
massel

PS: WHO-Update 59 fehlt immer noch (letztes ist nun 1 Woche her !!)

Antwort auf Beitrag Nr.: 37.563.368 von Massel am 13.07.09 19:16:25neueste Analystenempfehlung vom 13.07.

Rodman and Renshaw mit "Outperform" und Kursziel 5 USD.

Ich kenn die Jungs zwar nicht, aber dem Kurs hilfts

Gruss

die USA bestellt für 690 Mio bei Novartis Impfstoffe und hatten vor Monaten bereits für über 200 Mio bestellt. Auch bei Sanofi etc. wurden Impfoffe bestellt aber nicht in diesem Umfang. Ich frage mich manchmal, was NVAX genau macht, wenn mehrere Pharmafirmen diesen Impfstoff rasch und eff. herstellen können. Das Rad ist eben doch schon erfunden....ich frage nochmals bei NVAX nach was die Firma denn so speziell macht.

Uebrigens hab ich auch das KZ von neu 5$ bei RodmanandRenshaw nachgefragt, wie sie auf dieses Ziel kommen, doch keine Antwort bislang. Es waren aber diejenigen, welche vor Ausbruch der Schweinegrippe das KZ auf 4$ ansetzten mit der Begründung die Technologie werde sich am Markt durchsetzen....

"....ich frage nochmals bei NVAX nach was die Firma denn so speziell macht."....

Das ist genau die Frage, die ich mir auch stelle.
Wenn Du da mal ´ne Antwort bekommst, poste die bitte gleich.

Werde aus der Firma bisher noch nicht so 100%ig schlau